Perbandingan kadar hs-CRP pada penderita DM tipe 2 yang dislipidemi dan nondislipidemi
DAFTAR PUSTAKA
1. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di
Indonesia;Jakarta, PB Perkeni 2011;4-7.
2. Darmono,
Suhartono
T,Pemayun
TGD,
Padmomartono
FS.
Diabetes Melitus ditinjau dari berbagai aspek penyakit dalam.
Semarang:Badan Penerbit Universitas Diponegoro;2007:31-35.
3. Haffners,Lehto C, Ronnemaa T, Pyorala K, Laakso M: Mortality
from coronary heart disease in subjects with type 2 diabetes and
nondiabetic subjects with and without prior myocardial infarction.
New England Journal Medicine;1988 339:229-234.
4. Nadyah A, Yuanita AL, Karel P. Gambaran faktor resiko pasien
diabetes melitus tipe 2 di poliklinik endokrin bagian/smf fk Unsrat
RSU Prof.DR.dr.kandou Manado periode Mei 2011 – Oktober 2011.
Journal biomedik 2013;1;45 – 49.
5. Anubha M, Rubina T,Sreenivas C, OM Prakash D, Mausumi B, Nikil
T, dkk. High-Sensitivity C-Reactive Protein protein levels and type 2
diabetes in urban north Indians. Journal Clinical Endocrinol
Metabolisme 2009:94(6):2123-2127.
6. Edward THY. High sensitivity C-reactive protein as a risk
assessment
for
cardiovascular
disease.Clinical
cardiology.
2005;28:408-412.
45
Universitas Sumatera Utara
7. Kiran M, Brian GK, Roger SB, Valentin F, Catherine YC, TYJ
Gluckman et al.The use of high-sensitivity assays for C-reactive
protein in clinical practice.2008 ; 5:621 – 635.
8. Paul M.R, Charles H.H, Julie E.B, Nader R. C-reactive protein and
other markers of inflammation in the prediction of cardiovascular
disease in women. The new England journal of medicine
2000:342:836 – 843.
9. Shilpa BA, Morathe A, Tekad ML.High-Sensitivity CRP a novel
cardiovascular risk predictor in type 2 diabetics with normal lipid
profile. Diabetes and its complications Journal.2011; 25(6):368-370.
10. Palvasha W, Abdul Khaliq N, Fareeha F. Levels of inflammatory
markers and their correlation with dyslipidemia in diabetics. Journal
of the college of physicians and surgeons Pakistan 2009; 19 : 207 –
210.
11. D.Rajarajeswari,
J.N.
Naidu,
B.Sowjanya.
Association
of
dyslipidemia and inflammatory markers in type 2 diabetes mellitus.
International journal of applied biology and pharmaceutical
technology.2011;3:419 – 423.
12. Kosasih E.N,Kosasih A.S. Tafsiran hasil pemeriksaan laboratorium
klinik. Edisi ke 2; Karisma Publishing Group .Tangerang 2008; 275279.
13. Konsensus pengelolaan dislipidemi di Indonesia; Jakarta‟PERKENI
2012;16-20.
46
Universitas Sumatera Utara
14. Detection,evaluation, and treatment of high blood cholesterol in
adults (adults treatment panel III). National institutes of health 2002.
15. Diabetic dyslipidemia. American Diabetes Association:3:1- 4.
16. Riffat Sultana. Impact of Duration of type 2 Diabetes Mellitus on
Lipid
Profile.
Gomal
Journal
of
Internal
medical
Sciences.2010;8:57-59.
17. McPhee SJ. Ganong WF. Patofisiologi penyakit. Edisi ke 5;
Penerbit Buku Kedokteran EGC 2010.566 – 583.
18. Suryohudoyo P.Ilmu kedokteran molekuler. Sagung seto Jakarta
2007.58-65.
19. JB. Henry. Clinical Diagnosis and Management by Laboratory
methods, Ed 22, Saaunders, Philadelphia, 2011: 254 – 255.
20. Alan H.B Wu. Cardiac marker 2nd.Humana press;Totowe New
Jersey;2003.279-303.
21. WHO guidelines on drawing blood: best practices in phlebotomy
2010:7-28.
22. Automated Hematology Analyzer XT4000i. Instruction for use.
Sysmex Corporation Kobe, Japan.2010: 11.8 –11.10.
23. Lim H,Lindarto D,Zein U.Prinsip farmakologi endokrin-infeksi edisi 1
Jakarta,P.T sofmedia,2014.
24. Alwi I, Teguh S, Slamet S, Bambang S, Siti BK. Titik potong (cut off)
kadar high sensitive c- reactive protein pada pasien sindrom
koroner akut. Majalah kedokteran Indonesia 2010; 60 : 554- 558
47
Universitas Sumatera Utara
25. Aneta F, Piotr M,Krzystof S,Wieslaw P, Lilianna M. Increased
concentration of c-reactive protein in obese patients with type 2
diabetes is associated with obesity and presence of diabetes but
not with macrovascular and microvascular complications or
glycemic control.Inflammation 2014:37;349-356.
26. Brownlee M. The pathobiology of diabetic complications. A unifying
mechanism. Banting Lecture 2004. Diabetes.2005;54:1615-1624.
27. Corwin JE. Buku saku patofisiologi. Edisi ke 3; Penerbit Buku
Kedokteran EGC 2007.477-481.
28. David
AM.
Cardiovascular Biomarkers Pathophysiology and
Disease Management.New Jersey.Humana Press,2006.261 – 275
29. E.S Nakou, Elisaf, E.N.Liberopoulos.High-sensitivity C-reactive
protein:to measure or not to measure?.The open clinical journal
Chemistry journal 2010;3:10-18.
30. F Bello S, Ag Bakari, FE Anumah. Dyslipidemia in persons with
type 2 diabetes mellitus in Kaduna,Nigeria. International journal
diabetes and metabolism 2007:15;9-13.
31. I Wayan AJS, Ketut S. Hubungan antara kadar high sensitivity creactive protein dengan derajat asma bronchial akut. Jurnal
penyakit dalam 2011;12:175-180.
32. Luigi Giusto S, Elena Bonamno , Giuseppe Sangiorgi G, Alexandro
Mauriello. Role of inflammation in atherosclerosis. The journal of
nuclear medicine 2007; 48 : 1800 – 1815.
48
Universitas Sumatera Utara
33. Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Bharadwaj M,
Tandon N, dkk. High-Sensitivity C-Reactive Protein protein levels
and type 2 diabetes in urban north Indians. Journal Clin Endocrinol
Metab 2009:94(6):2123-2127.
34. McPhee SJ. Ganong WF. Patofisiologi penyakit. Edisi ke 5;
Penerbit Buku Kedokteran EGC 2010.566 – 583.
35. Pu LJ, XU Wui X,Zang RY,Zhang Q,Zang JS et al. Value of serum
glycated albumin and high sensitivity C reactive protein levels in the
prediction of presence of coronary artery disease in patients with
type 2 diabetes.Cardiovascular diabetology 2006,5.27
36. Shital SG, Ramchandra KP, Sonali SB, Rahul AG, Sangita M. hsCRP: a golden marker of inflammation and coronary artery
disease.International journal of health sciences and research
2012:2;42- 46.
37. Singh,Gurdeep,Kumar,Ashok. Impact of chronicity on lipid profile
nof type 2 diabetics.Journal of exercise science and physiotherapy
2013;9:46-50.
38. Thomas F.L, Mark AC, Joshua AB, Francesco C. Diabetes and
vascular disease: pathophysiology, clinical consequences and
medical
therapy:part
II.
American
Heart
Association
.2003:108:1655-1661.
49
Universitas Sumatera Utara
1. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di
Indonesia;Jakarta, PB Perkeni 2011;4-7.
2. Darmono,
Suhartono
T,Pemayun
TGD,
Padmomartono
FS.
Diabetes Melitus ditinjau dari berbagai aspek penyakit dalam.
Semarang:Badan Penerbit Universitas Diponegoro;2007:31-35.
3. Haffners,Lehto C, Ronnemaa T, Pyorala K, Laakso M: Mortality
from coronary heart disease in subjects with type 2 diabetes and
nondiabetic subjects with and without prior myocardial infarction.
New England Journal Medicine;1988 339:229-234.
4. Nadyah A, Yuanita AL, Karel P. Gambaran faktor resiko pasien
diabetes melitus tipe 2 di poliklinik endokrin bagian/smf fk Unsrat
RSU Prof.DR.dr.kandou Manado periode Mei 2011 – Oktober 2011.
Journal biomedik 2013;1;45 – 49.
5. Anubha M, Rubina T,Sreenivas C, OM Prakash D, Mausumi B, Nikil
T, dkk. High-Sensitivity C-Reactive Protein protein levels and type 2
diabetes in urban north Indians. Journal Clinical Endocrinol
Metabolisme 2009:94(6):2123-2127.
6. Edward THY. High sensitivity C-reactive protein as a risk
assessment
for
cardiovascular
disease.Clinical
cardiology.
2005;28:408-412.
45
Universitas Sumatera Utara
7. Kiran M, Brian GK, Roger SB, Valentin F, Catherine YC, TYJ
Gluckman et al.The use of high-sensitivity assays for C-reactive
protein in clinical practice.2008 ; 5:621 – 635.
8. Paul M.R, Charles H.H, Julie E.B, Nader R. C-reactive protein and
other markers of inflammation in the prediction of cardiovascular
disease in women. The new England journal of medicine
2000:342:836 – 843.
9. Shilpa BA, Morathe A, Tekad ML.High-Sensitivity CRP a novel
cardiovascular risk predictor in type 2 diabetics with normal lipid
profile. Diabetes and its complications Journal.2011; 25(6):368-370.
10. Palvasha W, Abdul Khaliq N, Fareeha F. Levels of inflammatory
markers and their correlation with dyslipidemia in diabetics. Journal
of the college of physicians and surgeons Pakistan 2009; 19 : 207 –
210.
11. D.Rajarajeswari,
J.N.
Naidu,
B.Sowjanya.
Association
of
dyslipidemia and inflammatory markers in type 2 diabetes mellitus.
International journal of applied biology and pharmaceutical
technology.2011;3:419 – 423.
12. Kosasih E.N,Kosasih A.S. Tafsiran hasil pemeriksaan laboratorium
klinik. Edisi ke 2; Karisma Publishing Group .Tangerang 2008; 275279.
13. Konsensus pengelolaan dislipidemi di Indonesia; Jakarta‟PERKENI
2012;16-20.
46
Universitas Sumatera Utara
14. Detection,evaluation, and treatment of high blood cholesterol in
adults (adults treatment panel III). National institutes of health 2002.
15. Diabetic dyslipidemia. American Diabetes Association:3:1- 4.
16. Riffat Sultana. Impact of Duration of type 2 Diabetes Mellitus on
Lipid
Profile.
Gomal
Journal
of
Internal
medical
Sciences.2010;8:57-59.
17. McPhee SJ. Ganong WF. Patofisiologi penyakit. Edisi ke 5;
Penerbit Buku Kedokteran EGC 2010.566 – 583.
18. Suryohudoyo P.Ilmu kedokteran molekuler. Sagung seto Jakarta
2007.58-65.
19. JB. Henry. Clinical Diagnosis and Management by Laboratory
methods, Ed 22, Saaunders, Philadelphia, 2011: 254 – 255.
20. Alan H.B Wu. Cardiac marker 2nd.Humana press;Totowe New
Jersey;2003.279-303.
21. WHO guidelines on drawing blood: best practices in phlebotomy
2010:7-28.
22. Automated Hematology Analyzer XT4000i. Instruction for use.
Sysmex Corporation Kobe, Japan.2010: 11.8 –11.10.
23. Lim H,Lindarto D,Zein U.Prinsip farmakologi endokrin-infeksi edisi 1
Jakarta,P.T sofmedia,2014.
24. Alwi I, Teguh S, Slamet S, Bambang S, Siti BK. Titik potong (cut off)
kadar high sensitive c- reactive protein pada pasien sindrom
koroner akut. Majalah kedokteran Indonesia 2010; 60 : 554- 558
47
Universitas Sumatera Utara
25. Aneta F, Piotr M,Krzystof S,Wieslaw P, Lilianna M. Increased
concentration of c-reactive protein in obese patients with type 2
diabetes is associated with obesity and presence of diabetes but
not with macrovascular and microvascular complications or
glycemic control.Inflammation 2014:37;349-356.
26. Brownlee M. The pathobiology of diabetic complications. A unifying
mechanism. Banting Lecture 2004. Diabetes.2005;54:1615-1624.
27. Corwin JE. Buku saku patofisiologi. Edisi ke 3; Penerbit Buku
Kedokteran EGC 2007.477-481.
28. David
AM.
Cardiovascular Biomarkers Pathophysiology and
Disease Management.New Jersey.Humana Press,2006.261 – 275
29. E.S Nakou, Elisaf, E.N.Liberopoulos.High-sensitivity C-reactive
protein:to measure or not to measure?.The open clinical journal
Chemistry journal 2010;3:10-18.
30. F Bello S, Ag Bakari, FE Anumah. Dyslipidemia in persons with
type 2 diabetes mellitus in Kaduna,Nigeria. International journal
diabetes and metabolism 2007:15;9-13.
31. I Wayan AJS, Ketut S. Hubungan antara kadar high sensitivity creactive protein dengan derajat asma bronchial akut. Jurnal
penyakit dalam 2011;12:175-180.
32. Luigi Giusto S, Elena Bonamno , Giuseppe Sangiorgi G, Alexandro
Mauriello. Role of inflammation in atherosclerosis. The journal of
nuclear medicine 2007; 48 : 1800 – 1815.
48
Universitas Sumatera Utara
33. Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Bharadwaj M,
Tandon N, dkk. High-Sensitivity C-Reactive Protein protein levels
and type 2 diabetes in urban north Indians. Journal Clin Endocrinol
Metab 2009:94(6):2123-2127.
34. McPhee SJ. Ganong WF. Patofisiologi penyakit. Edisi ke 5;
Penerbit Buku Kedokteran EGC 2010.566 – 583.
35. Pu LJ, XU Wui X,Zang RY,Zhang Q,Zang JS et al. Value of serum
glycated albumin and high sensitivity C reactive protein levels in the
prediction of presence of coronary artery disease in patients with
type 2 diabetes.Cardiovascular diabetology 2006,5.27
36. Shital SG, Ramchandra KP, Sonali SB, Rahul AG, Sangita M. hsCRP: a golden marker of inflammation and coronary artery
disease.International journal of health sciences and research
2012:2;42- 46.
37. Singh,Gurdeep,Kumar,Ashok. Impact of chronicity on lipid profile
nof type 2 diabetics.Journal of exercise science and physiotherapy
2013;9:46-50.
38. Thomas F.L, Mark AC, Joshua AB, Francesco C. Diabetes and
vascular disease: pathophysiology, clinical consequences and
medical
therapy:part
II.
American
Heart
Association
.2003:108:1655-1661.
49
Universitas Sumatera Utara